Founder and CEO
(Second-time founder)
Stanford postdoc (heart failure); PhD (vascular aging).
Built the computational workflow for designing the lead series.
4 years biotech industry experience in translational drug development and clinical research.
Scoped synthesis and functional cleavage protocols with CRO partners.
Biomarker strategy validated with leading HFpEF Key Opinion Leadership.